Key Points
- Carl Dambkowski sold 18,700 Apogee Therapeutics shares on Jan. 7 at an average price of $77.84 for $1,455,608, reducing his ownership by 8.09% to 212,523 shares valued at about $16.54M; he also sold shares on Dec. 4 and Nov. 5.
- Apogee Therapeutics shares trade near $78 with a 12‑month range of $26.20–$80.99 and a $5.33B market cap, and analysts hold a consensus "Moderate Buy" with a $104.27 price target while the company advances APG‑157, an oral RORγt inverse agonist for plaque psoriasis.
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 18,700 shares of the business's stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $77.84, for a total transaction of $1,455,608.00. Following the transaction, the insider directly owned 212,523 shares in the company, valued at $16,542,790.32. The trade was a 8.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Carl Dambkowski also recently made the following trade(s):
- On Thursday, December 4th, Carl Dambkowski sold 10,900 shares of Apogee Therapeutics stock. The stock was sold at an average price of $75.00, for a total transaction of $817,500.00.
- On Wednesday, November 5th, Carl Dambkowski sold 10,785 shares of Apogee Therapeutics stock. The shares were sold at an average price of $55.07, for a total transaction of $593,929.95.
Apogee Therapeutics Stock Up 0.7%
Apogee Therapeutics stock opened at $77.99 on Friday. Apogee Therapeutics Inc. has a 12 month low of $26.20 and a 12 month high of $80.99. The stock has a market cap of $5.33 billion, a P/E ratio of -17.81 and a beta of 1.41. The company's fifty day simple moving average is $70.89 and its 200-day simple moving average is $51.85.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.03. On average, equities research analysts expect that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on APGE. Stifel Nicolaus set a $133.00 price target on Apogee Therapeutics in a report on Tuesday. UBS Group raised shares of Apogee Therapeutics to a "strong-buy" rating in a research report on Wednesday. Stephens started coverage on shares of Apogee Therapeutics in a research note on Tuesday, December 16th. They set an "overweight" rating and a $95.00 price target on the stock. Wolfe Research initiated coverage on shares of Apogee Therapeutics in a research note on Wednesday. They issued a "peer perform" rating for the company. Finally, Craig Hallum reiterated a "buy" rating and issued a $116.00 price objective on shares of Apogee Therapeutics in a report on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $104.27.
Check Out Our Latest Research Report on Apogee Therapeutics
Hedge Funds Weigh In On Apogee Therapeutics
Institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Apogee Therapeutics by 2.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company's stock worth $921,000 after buying an additional 694 shares during the last quarter. Millennium Management LLC raised its holdings in Apogee Therapeutics by 100.0% in the 1st quarter. Millennium Management LLC now owns 260,335 shares of the company's stock worth $9,726,000 after acquiring an additional 130,164 shares during the period. Rhumbline Advisers lifted its position in Apogee Therapeutics by 3.2% during the 1st quarter. Rhumbline Advisers now owns 54,385 shares of the company's stock worth $2,032,000 after acquiring an additional 1,665 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Apogee Therapeutics by 18.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company's stock worth $77,000 after acquiring an additional 272 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new stake in Apogee Therapeutics during the second quarter valued at about $218,000. Institutional investors own 79.04% of the company's stock.
About Apogee Therapeutics
(
Get Free Report)
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
